GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avax Technologies Inc (OTCPK:AVXT) » Definitions » COGS-to-Revenue

Avax Technologies (Avax Technologies) COGS-to-Revenue : 0.00 (As of Sep. 2008)


View and export this data going back to . Start your Free Trial

What is Avax Technologies COGS-to-Revenue?

Avax Technologies's Cost of Goods Sold for the three months ended in Sep. 2008 was $0.00 Mil. Its Revenue for the three months ended in Sep. 2008 was $0.20 Mil.

Avax Technologies's COGS to Revenue for the three months ended in Sep. 2008 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Avax Technologies's Gross Margin % for the three months ended in Sep. 2008 was N/A%.


Avax Technologies COGS-to-Revenue Historical Data

The historical data trend for Avax Technologies's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avax Technologies COGS-to-Revenue Chart

Avax Technologies Annual Data
Trend Dec98 Dec99 Dec00 Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Avax Technologies Quarterly Data
Dec03 Mar04 Jun04 Sep04 Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Avax Technologies COGS-to-Revenue Calculation

Avax Technologies's COGS to Revenue for the fiscal year that ended in Dec. 2007 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0.617
=0.00

Avax Technologies's COGS to Revenue for the quarter that ended in Sep. 2008 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0.2
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avax Technologies  (OTCPK:AVXT) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Avax Technologies's Gross Margin % for the three months ended in Sep. 2008 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0.2
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Avax Technologies COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Avax Technologies's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Avax Technologies (Avax Technologies) Business Description

Traded in Other Exchanges
N/A
Address
9200 Indian Creek Parkway, Suite 200, Overland Park, KS, USA, 66210
Avax Technologies Inc is a development stage biotechnology company. The company is engaged in the development and commercialization of individualized vaccine therapies and other technologies for the treatment of cancer. It also involved in the development and commercial readiness in the immuno-oncology arena.
Executives
Carl Spana director PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Prendergast John K A director ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017

Avax Technologies (Avax Technologies) Headlines

No Headlines